1. Chagas disease and liver transplantation: Experience in Argentina using real-time quantitative PCR for early detection and treatment
- Author
-
Alvaro Alcaraz, Domingo Balderramo, Florencia Bonisconti, Ariel German Sanchez, Enzo Giordano, T Alvarellos, Juan Pablo Caeiro, Martín Barrabino, and Martin Maraschio
- Subjects
Adult ,Male ,Chagas disease ,Trypanosoma cruzi ,medicine.medical_treatment ,Argentina ,Parasitemia ,030230 surgery ,Liver transplantation ,Real-Time Polymerase Chain Reaction ,End Stage Liver Disease ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Preoperative Care ,parasitic diseases ,Humans ,Medicine ,Chagas Disease ,Serologic Tests ,Cumulative incidence ,Prospective Studies ,Aged ,Transplantation ,biology ,business.industry ,Incidence ,Zoonosis ,DNA, Protozoan ,Middle Aged ,medicine.disease ,biology.organism_classification ,Trypanocidal Agents ,Tissue Donors ,Transplant Recipients ,Liver Transplantation ,Infectious Diseases ,Real-time polymerase chain reaction ,Cohort ,Immunology ,Female ,030211 gastroenterology & hepatology ,business ,Follow-Up Studies - Abstract
Background Chagas disease (CD) is an endemic zoonosis that occurs in Latin-America and is caused by the parasite Trypanosoma cruzi. Early detection of T. cruzi in liver transplant recipients at risk may avoid complications from CD. The aim of this study was to examine the pre-operative evaluation and follow-up of CD after liver transplantation (LT) of patients at risk of CD using real-time quantitative polymerase chain reaction (qPCR) for T. cruzi. Methods Between January 2009 and June 2016, 13 (12.7%) of 102 LTs performed in recipients at risk for CD without specific postoperative prophylaxis were prospectively evaluated using qPCR for T. cruzi. Four seronegative patients received livers from seropositive donors (R-/D+) and 9 seropositive recipients received livers from seronegative donors (R+/D-). A cohort of 89 patients without risk for CD during the same time period was analyzed as controls. Results A positive qPCR for T. cruzi prior to LT was found in 2/9 (22.2%) seropositive recipients, and both achieved early response after therapy. The cumulative incidence of positive parasitemia after LT was higher in R+/D- than R-/D+ (37.7% vs 0%, P = .17). R+/D- transplant patients with positive qPCR achieved therapeutic response without manifestations of acute CD. LT outcomes at 1 year were similar in patients at risk of CD and in controls not at risk for CD. Conclusion A small proportion of T. cruzi-seropositive candidates presented positive parasitemia before LT. After LT, qPCR allowed detection of parasitemia leading to use of preemptive therapy in all R+/D- with T. cruzi replication. No cases of T. cruzi parasitemia occurred in R-/D+. This article is protected by copyright. All rights reserved.
- Published
- 2017